<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755675</url>
  </required_header>
  <id_info>
    <org_study_id>AK-2015-LC-1</org_study_id>
    <nct_id>NCT02755675</nct_id>
  </id_info>
  <brief_title>uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      uPAR PET/CT as a prognostic marker in non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study I: uPAR PET/CT with 68Ga-NOTA-AE105 will be evaluated as a prognostic tool in patients
      with non-small cell lung cancer (NSCLC) (stage IV (Ia) operable disease (Ib)) by
      observer-blinded readings and compared to the prognostic performance of FDG PET/CT and
      prognostic biomarkers as uPAR.

      Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant
      pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung
      (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Ia: Overall survival (OS)</measure>
    <time_frame>Study Ia: OS is evaluated after clinical follow-up for 18 months (stage IV disease)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study Ib: Overall survival (OS)</measure>
    <time_frame>Study Ib: OS is evaluated after clinical follow-up for 60 months (operable disease)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study II and III: Uptake of 68Ga-NOTA-AE105 in primary tumor lesion (dichotomized +/-)</measure>
    <time_frame>Study II and III: Uptake of 68Ga-NOTA-AE105 is evaluated based on PET/CT scans performed within 1 hour post injection of 68Ga-NOTA-AE105</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Ia: Progression free survival (PFS)</measure>
    <time_frame>Study Ia: PFS is evaluated after clinical follow-up for 18 months (stage IV disease)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Ib: Disease free survival (DFS)</measure>
    <time_frame>Study Ib: DFS is evaluated after clinical follow-up for 60 months (operable disease)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Malignant Pleural Mesothelioma</condition>
  <condition>Large Cell Neuroendocrine Carcinoma of the Lung</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA-AE105 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>68Ga-NOTA-AE105 PET/CT</intervention_name>
    <description>Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT</description>
    <arm_group_label>68Ga-NOTA-AE105 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study I

          -  Histologically verified NSCLC (Study I)

          -  Stage IV disease

          -  Operable disease

          -  The participants must be capable of understanding and giving full informed written
             consent

        Study II

          -  Histologically verified MPM (Study II)

          -  The participants must be capable of understanding and giving full informed written
             consent

        Study III

          -  Histologically verified LCNEC (Study III)

          -  The participants must be capable of understanding and giving full informed written
             consent

        Exclusion Criteria:

        Study I, II, III

          -  Pregnancy

          -  Lactation/breast feeding

          -  Treatment with neoadjuvant chemotherapy

          -  Weight above 140 kg

          -  Allergy to 68Ga-NOTA-AE105
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Malene M Clausen, MD, PhD</last_name>
    <phone>+4522524536</phone>
    <email>malene.martini.clausen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Kjaer, MD,DMSc,PhD</last_name>
    <phone>+4535454011</phone>
    <email>akjaer@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malene M Clausen, MD, PhD</last_name>
      <phone>+4522524536</phone>
      <email>malene.martini.clausen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Kjaer, Professor, MD, DMSc, PhD</last_name>
      <phone>+4535454011</phone>
      <email>akjaer@sund.ku.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Malene M Clausen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>November 18, 2016</last_update_submitted>
  <last_update_submitted_qc>November 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Malene Martini Clausen</investigator_full_name>
    <investigator_title>MD, PhD, postdoc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

